BioArctic
Develops treatments and diagnostics for neurodegenerative disorders like Alzheimer's and Parkinson's.
BIOA | ST
Overview
Corporate Details
- ISIN(s):
- SE0010323303 (+1 more)
- LEI:
- 549300Y0OI2WVUNHLC33
- Country:
- Sweden
- Address:
- Warfvinges väg 35, 112 51 Stockholm
- Website:
- https://www.bioarctic.se/en/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
BioArctic is a Swedish research-intensive biopharmaceutical company focused on developing novel, disease-modifying treatments and diagnostics for neurodegenerative disorders. The company's core mission is to address the underlying causes of diseases such as Alzheimer's and Parkinson's. Its research is centered on developing innovative drugs and antibodies that target the root mechanisms of nerve cell damage and misfolded proteins, aiming to provide effective solutions for significant unmet medical needs within the central nervous system.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-08-01 12:45 |
Leqembi revenue more than doubled – totaled JPY 6.3 billion in the second quart…
|
English | 173.0 KB | ||
| 2024-07-30 23:00 |
Long-term lecanemab data show increased patient benefit with maintained safety …
|
English | 232.7 KB | ||
| 2024-07-30 23:00 |
Långtidsdata för lecanemab visar ökande patientnytta med bibehållen säkerhetspr…
|
Swedish | 216.9 KB | ||
| 2024-07-26 13:15 |
Eisai ansöker om omprövning av CHMP-besked gällande lecanemab
|
Swedish | 194.5 KB | ||
| 2024-07-26 13:15 |
Eisai will seek re-examination of CHMP opinion för lecanemab
|
English | 190.7 KB | ||
| 2024-07-26 12:40 |
CHMP has adopted a negative opinion on lecanemab for the EU
|
English | 180.1 KB | ||
| 2024-07-12 01:30 |
Leqembi approved for the treatment of Alzheimer’s disease in Israel
|
English | 181.8 KB | ||
| 2024-07-12 01:30 |
Leqembi godkänt för behandling av Alzheimers sjukdom i Israel
|
Swedish | 204.2 KB | ||
| 2024-07-11 01:30 |
Leqembi approved for the treatment of Alzheimer’s disease in Hong Kong
|
English | 235.5 KB | ||
| 2024-07-11 01:30 |
Leqembi godkänt för behandling av Alzheimers sjukdom i Hong Kong
|
Swedish | 267.2 KB | ||
| 2024-06-28 18:30 |
Number of shares and votes in BioArctic AB (publ) as of June 28, 2024
|
English | 138.0 KB | ||
| 2024-06-28 18:30 |
Antal aktier och röster i BioArctic AB (publ) per den 28 juni 2024
|
Swedish | 137.8 KB | ||
| 2024-06-28 01:30 |
Leqembi[®] (lecanemab) launched in China
|
English | 274.5 KB | ||
| 2024-06-28 01:30 |
Leqembi[®] (lecanemab) lanserat i Kina
|
Swedish | 241.8 KB | ||
| 2024-06-10 01:30 |
FDA accepterar tilläggsansökan för månatlig intravenös underhållsbehandling av …
|
Swedish | 231.1 KB |
Automate Your Workflow. Get a real-time feed of all BioArctic filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BioArctic
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BioArctic via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-02-13 | Gunilla Osswald | Other | Sell | 40,000 | 8,821,200.00 SEK |
| 2025-02-13 | Gunilla Osswald | Other | Other | 40,000 | 3,344,000.00 SEK |
| 2025-02-13 | Sten Mikael Moge | Other | Sell | 6,000 | 1,323,180.00 SEK |
| 2025-02-13 | Sten Mikael Moge | Other | Other | 6,000 | 501,600.00 SEK |
| 2025-02-13 | Johanna Margareta Fälting | Other | Sell | 1,500 | 330,795.00 SEK |
| 2025-02-13 | Johanna Margareta Fälting | Other | Other | 2,500 | 209,000.00 SEK |
| 2025-02-13 | Johanna Margareta Fälting | Other | Other | 1,500 | 125,400.00 SEK |
| 2025-01-10 | Mikael Smedeby | Other | Buy | 730 | 148,920.00 SEK |
| 2024-12-19 | Oskar Bosson | Other | Sell | 2,000 | 446,000.00 SEK |
| 2024-12-19 | Oskar Bosson | Other | Sell | 871 | 195,626.60 SEK |
Peer Companies
